The Allergic Rhinitis Drugs Market Report 2023-2033: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Advent of Innovative Intranasal Therapies for Treatment of Allergic Rhinitis
Intranasal therapies are gaining acceptance owing to their better safety and efficacy. This route of administration is also recommended by physicians and allergists since they do not have any systemic side-effects and their adequate concentrations can be achieved at receptor sides in nasal mucosa. Their adverse effects are limited to dryness, sneezing and stinging of nasal mucosa. Several companies are developing innovative intranasal drugs owing to their inherent advantages over other routes of administration. For instance, ClorNasal™ developed by Dr. Ferrer BioPharma is recognized as the best intranasal pharm...

The Dermatology Drugs Market Report 2022-2032: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Factors Such As the Impact of Skin Disease on Quality Of Life and the Resulting Need to Tackle This Are Driving the Market Growth
WHO (World Health Organization) defined it as disability in skin conditions that impact the well-being, mental health, ability to function, and social participation and restrict engagement with others. Quality of life (QoL) tools help in these and some of the tools include the Dermatology Life Quality Index (DLQI) and the Skindex. The QoL can be impaired for a variety of reasons mainly due to symptoms of the disease. Atopic eczema is one disease where the psychological burden is particularly pronounced. Psychosomatic involvement is the main characteristic of atopic...

The Antiviral Drugs Market Report 2022-2032: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Introduction of Blockbuster Drugs to Boost Market Growth
Antiviral medicines are being actively researched and developed by a number of major pharmaceutical companies. Antiretroviral therapy has evolved dramatically since the emergence of blockbuster medications like Gilead Science's Biktarvy and GlaxoSmithKline's Triumeq. The antiviral market revenue is expected to grow between 2022 and 2032 because to rising consumption of such blockbuster medicines and increased distribution by producers.

The demand for antiviral medications has increased due to the COVID-19 pandemic. Due to a sharp increase in COVID-19 cases and healthcare facilities focusing their efforts primarily on tre...

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Spinal Cord Injury - Drugs In Development, 2022, provides an overview of the Spinal Cord Injury (Central Nervous System) pipeline landscape.

Spinal cord injury (SCI) is defined as damage or trauma caused to the spinal cord. SCI can lead to loss or impaired function resulting in reduced mobility or feeling. It is usually caused by trauma, transverse myelitis, polio, spina bifida or Friedreich's ataxia. Signs and symptoms of spinal cord injury include extreme back pain or pressure in the neck, head or back, paralysis in any part of the body, numbness, tingling or loss of sensation in the hands, fingers, feet or toes, loss of bladder or bowel control, difficulty in walking and impaired breathing after injury.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Spinal Cord Injury - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Spinal Cord Injury...

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gastritis - Drugs In Development, 2022, provides an overview of the Gastritis (Gastrointestinal) pipeline landscape.

Gastritis is characterized by inflammation or swelling of the lining of the stomach. Acute gastritis lasts for a short period of time while chronic gastritis lasts for a long period of time (months to years). Gastritis can be caused by medications such as ibuprofen, aspirin, naproxen on long periods of consumption, excess intake of alcohol, Helicobacter pylori infection, certain autoimmune disorders, bile reflux, substance abuse (cocaine), consumption of corrosive or caustic substances such as poisons, extreme stress, viral infections and trauma. The symptoms of gastritis may include loss of appetite, nausea and vomiting, abdominal pain and black stools. Treatment includes use of antacids, Histamine 2 (H2) antagonists and proton pump inhibitors.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipelin...

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ebolavirus Infections (Ebola Hemorrhagic Fever) - Drugs In Development, 2022, provides an overview of the Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease) pipeline landscape.

Ebola is a rare but deadly viral infection that causes bleeding inside and outside the body. Signs and symptoms include fever, severe headache, joint and muscle aches, sore throat, nausea and vomiting, diarrhea, chest pain and cough. Supportive therapy includes oxygen therapy, blood transfusions, intravenous fluids and pain relievers.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ebolavirus Infections (Ebola Hemorrhagic Fever) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Ebolavirus Infections (Ebola Hemorrhagic Fever) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administrat...

Summary

Diabetic Neuropathic Pain Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Diabetic Neuropathic Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diabetic Neuropathic Pain, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The report is built using data and information sourced from Global Markets Direct’s proprietar...

Summary

Surgical Wound Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Surgical Wound Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Surgical Wound Infections, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The report is built using data and information sourced from Global Markets Direct’s proprietar...

Summary

Non-Proliferative Diabetic Retinopathy (NPDR) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Non-Proliferative Diabetic Retinopathy (NPDR) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Non-Proliferative Diabetic Retinopathy (NPDR), complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The report is built using data and i...

Summary

Heat Shock Protein 70 (HSP70) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Heat Shock Protein 70 (HSP70) targeted pipeline therapeutics. The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Additionally, the report analyses the pipeline products across relevant therapy areas under development and provides an overview of key players involved in Heat Shock Protein 70 (HSP70) targeted therapeutics development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantag...

Summary

Thymoma (Thymic Epithelial Tumor) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Thymoma (Thymic Epithelial Tumor) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Thymoma (Thymic Epithelial Tumor), complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The report is built using data and information sourced from Global Marke...

Summary

Multidrug Resistance Protein 1 (ATP Binding Cassette Sub Family B Member 1 or P Glycoprotein 1 or CD243 or ABCB1 or EC 7.6.2.2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Multidrug Resistance Protein 1 (ATP Binding Cassette Sub Family B Member 1 or P Glycoprotein 1 or CD243 or ABCB1 or EC 7.6.2.2) targeted pipeline therapeutics. The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Additionally, the report analyses the pipeline products across relevant therapy areas under development and provides an overview of key players involved in Multidrug Resistance Protein 1 (ATP Binding Cassette Sub Family B Member 1 or P Glycoprotein 1 or CD243 or ABCB1 or EC 7.6.2.2) targeted...

Summary

Sleep Disorders Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Sleep Disorders pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Sleep Disorders, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/universit...

Summary

Sodium Channel Protein Type 4 Subunit Alpha (Sodium Channel Protein Skeletal Muscle Subunit Alpha or Voltage Gated Sodium Channel Subunit Alpha Nav1.4 or SCN4A) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Sodium Channel Protein Type 4 Subunit Alpha (Sodium Channel Protein Skeletal Muscle Subunit Alpha or Voltage Gated Sodium Channel Subunit Alpha Nav1.4 or SCN4A) targeted pipeline therapeutics. The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Additionally, the report analyses the pipeline products across relevant therapy areas under development and provides an overview of key players involved in Sodium Channel Protein Type 4 Subunit Alpha (Sodium Channel Protein Sk...

Summary

Neuromuscular Disorders Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Neuromuscular Disorders pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Neuromuscular Disorders, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The report is built using data and information sourced from Global Markets Direct’s proprietary data...

Summary

Vasopressin V2 Receptor (AVPR V2 or Antidiuretic Hormone Receptor or Renal Type Arginine Vasopressin Receptor or ADHR or AVPR2) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Vasopressin V2 Receptor (AVPR V2 or Antidiuretic Hormone Receptor or Renal Type Arginine Vasopressin Receptor or ADHR or AVPR2) targeted pipeline therapeutics. The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Additionally, the report analyses the pipeline products across relevant therapy areas under development and provides an overview of key players involved in Vasopressin V2 Receptor (AVPR V2 or Antidiuretic Hormone Receptor or Renal Type Arginine Vasopressin Receptor or ADHR or AVPR2) targeted...

Summary

Chordoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Chordoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chordoma, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical ...

Summary

Vitamin D3 Receptor (1,25 Dihydroxyvitamin D3 Receptor or Nuclear Receptor Subfamily 1 Group I Member 1 or NR1I1 or VDR) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Vitamin D3 Receptor (1,25 Dihydroxyvitamin D3 Receptor or Nuclear Receptor Subfamily 1 Group I Member 1 or NR1I1 or VDR) targeted pipeline therapeutics. The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Additionally, the report analyses the pipeline products across relevant therapy areas under development and provides an overview of key players involved in Vitamin D3 Receptor (1,25 Dihydroxyvitamin D3 Receptor or Nuclear Receptor Subfamily 1 Group I Member 1 or NR1I1 or VDR) targeted therapeutics develop...

Summary

Sezary Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Sezary Syndrome pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Sezary Syndrome, complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/universit...

Summary

Cells Expressing T Cell Antigen CD7 (GP40 or T Cell Leukemia Antigen or T Cell Surface Antigen Leu 9 or TP41 or CD7) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Cells Expressing T Cell Antigen CD7 (GP40 or T Cell Leukemia Antigen or T Cell Surface Antigen Leu 9 or TP41 or CD7) targeted pipeline therapeutics. The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Additionally, the report analyses the pipeline products across relevant therapy areas under development and provides an overview of key players involved in Cells Expressing T Cell Antigen CD7 (GP40 or T Cell Leukemia Antigen or T Cell Surface Antigen Leu 9 or TP41 or CD7) targeted therapeutics development and fea...

Summary

Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis), complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effecti...

Summary

Clostridium difficile Toxin B (toxB or EC 3.4.22.) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Clostridium difficile Toxin B (toxB or EC 3.4.22.) targeted pipeline therapeutics. The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Additionally, the report analyses the pipeline products across relevant therapy areas under development and provides an overview of key players involved in Clostridium difficile Toxin B (toxB or EC 3.4.22.) targeted therapeutics development and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to c...